Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization,Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial |
| |
Authors: | Mel Krajden Darrel Cook Amanda Yu Ron Chow Qiang Su Wendy Mei Shelly McNeil Deborah Money Marc Dionne Joel Palefsky Karuna Karunakaran Tobias Kollmann Gina Ogilvie Martin Petric Simon Dobson |
| |
Affiliation: | 1. British Columbia Centre for Disease Control, 655 West 12th Avenue, Vancouver, Canada;2. Faculty of Medicine, University of British Columbia, 317 – 2194 Health Sciences Mall, Vancouver, Canada;3. Provincial Health Services Authority Laboratories, 655 West 12th Avenue, Vancouver, Canada;4. Centre for Vaccinology, Dalhousie University, 5850 University Avenue, Halifax, Canada;5. Centre de recherche du CHUL, Université Laval, 2400 D’Estimauville, Québec, Canada;6. University of California San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143, USA;g Vaccine Evaluation Centre, BC Children''s Hospital, 950 West 28th Avenue, Vancouver, Canada |
| |
Abstract: | We assessed HPV 16 and 18 antibody responses of female subjects enrolled in a 2- vs. 3-dose quadrivalent HPV (Q-HPV) vaccine trial (ClinicalTrials.gov NCT00501137) using the Merck competitive Luminex (cLIA) and total IgG Luminex (TIgG) immunoassays, and a pseudovirus neutralizing antibody (PsV NAb) assay. Subjects were enrolled in one of three groups: (1) 9–13 yr, 2 doses of Q-HPV at 0, 6 months (n = 259); (2) 9–13 yr, 3 doses at 0, 2, 6 months (n = 260); and (3) 16–26 yr, 3 doses at 0, 2, 6 months (n = 305). Sera were collected from all subjects at baseline, months 7 and 24, and from half the subjects at months 18 and 36. High correlation was observed between all three assays. At month 36, HPV 16 antibodies remained detectable in all subjects by all assays, whereas 86.4%, 99.6% and 100% of subjects respectively were HPV 18 cLIA, TIgG and PsV NAb (partial neutralization endpoint) seropositive. The proportion seropositive for HPV 18 by cLIA at 36 months was not significantly different for 2-dose girls vs. 3-dose adults (85.9% vs. 79.4%; p = 0.51), whereas the proportion for 3-dose girls was significantly higher than for 3-dose adults (95.3% vs. 79.4%; p < 0.01). The HPV 18 seropositive proportions by the TIgG and PsV NAb (partial neutralization endpoint) assays were the same for all subjects. High baseline HPV 16 and HPV 18 seropositivity was observed for the TIgG assay and it is unclear if all the detected TIgG antibodies are type-specific and/or neutralizing. For the PsV NAb assay, 90% and partial neutralization geometric mean titres were consistently 2–8-fold higher than for 100% neutralization, which enabled detection of HPV 18 NAb in subjects who lost detectable cLIA antibodies over time. We conclude that the PsV NAb assay is more sensitive than the cLIA, and likely more specific than the TIgG assay. |
| |
Keywords: | cLIA, Merck competitive Luminex immunoassay EIA, enzyme immunoassay GMT, geometric mean titre mMU, milli-Merck units NT100, 100% neutralization endpoint NT90, 90% neutralization endpoint NTpartial, partial neutralization endpoint PsV NAb, pseudovirus neutralizing antibody Q-HPV, quadrivalent HPV RFP, red fluorescent protein TIgG, Merck total IgG Luminex immunoassay VLP, virus-like particle |
本文献已被 ScienceDirect 等数据库收录! |
|